Vertex Pharmaceuticals (VRTX) FY2024 results: revenue $11.0 billion, up 11.7% on the year
Vertex Pharmaceuticals Inc. (VRTX) reported revenue of $11.0 billion for fiscal 2024, the year ended 31 December 2024, up 11.7% on the year before. Net income was -$536 million, and diluted earnings per share $-2.08. The figures are the company's own, from the 10-K it filed with the SEC on 13 February 2025.
Revenue
$11.0 billion
+11.7% on the year
FY2017FY2024
Operating margin
-2.1%
38.8% a year earlier
FY2017FY2024
Net income
-$536 million
FY2017FY2024
Diluted EPS
-$2.08
FY2017FY2024
this yearthe year beforeHover a bar for its figure.
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2024
FY2023
FY2022
On the year
Last 8 years
Operating cash flow
-493
3,537
4,130
Capital expenditure
298
200
205
+48.6%
Free cash flow
-790
3,337
3,925
Free cash flow margin
-7.2%
33.8%
44.0%
Cash from investing
-3,770
-3,142
-321
Cash from financing
-1,495
-562
-67.7
Depreciation and amortisation
207
181
148
+14.3%
Share-based compensation
698
581
491
+20.2%
Buybacks
1,177
428
0.0
+175.3%
Diluted shares, weighted
258m
260m
259m
-1.0%
Shares outstanding at period end
257m
258m
257m
-0.3%
Balance sheet
$ million
FY2024
FY2023
FY2022
On the year
Last 8 years
Shareholders' equity
16,410
17,580
13,913
-6.7%
Debt
0.0
0.0
0.0
Operating lease liabilities
1,544
349
380
+343.0%
Finance lease liabilities
113
376
431
-70.0%
Other liabilities
4,466
4,425
3,428
+0.9%
Total liabilities and equity
22,533
22,730
18,151
-0.9%
Goodwill
1,088
1,088
1,088
0.0%
Intangible assets
826
840
604
-1.7%
Investments
6,654
3,347
387
+98.8%
Cash and equivalents
4,570
10,369
10,504
-55.9%
Receivables
1,609
1,563
1,442
+2.9%
Inventory
1,205
739
461
+63.2%
Other assets
6,581
4,784
3,666
+37.6%
Total assets
22,533
22,730
18,151
-0.9%
10-K for the year ended 31 December 2024, filed 13 February 2025: the filing.